HitGen Inc.

HitGen Inc. is a biotechnology company that engages in the development of novel medicines. Its key focus is harnessing its proprietary DNA-encoded library (DEL) technology to facilitate the discovery of new drug leads. This advanced platform enables the screening of vast libraries of chemical compounds swiftly and efficiently, targeting a wide range of molecular structures. HitGen’s technology has significant implications across various sectors within the pharmaceutical industry, particularly in drug discovery and development for diseases such as cancer, autoimmune disorders, and infectious diseases. HitGen collaborates globally with pharmaceutical companies, biotechnology firms, and research institutions, providing critical resources to enhance drug pipeline advancements. Headquartered in China, HitGen is a publicly traded company that adds value to the healthcare industry through its contributions to innovative therapeutics and has established a notable presence in the field of drug discovery. The company's work is integral to advancing the capabilities of organizations seeking advanced solutions in the early stages of pharmaceutical development.